Here are five things to know:
1. The medical device company industry has long been acquainted with mergers and acquisitions activity. Big companies seek new therapies and small companies position themselves as acquisition-worthy targets.
2. Today, M&A activity proves more strategic than in the past, with big companies looking to dominate an entire space, thus offering a comprehensive solution.
3. Regulatory demand, tax issues, reimbursement and pricing all increased M&A activity outside of the United States.
4. Further, the lengthy FDA-approval process forces companies to band together to survive losses accrued during the intermittent time.
5. Zacks recommends investors focus on stock where consolidation will prove beneficial. For example, the firm highlights NuVasive as a “strong buy,” following its deal to acquire Biotronic NeuroNetwork.
More articles on devices:
NuVasive, Bioventus, DFINE & more: 17 key notes
Medtech sells 13 ROSA robots in Q4 2016 — 5 highlights
Dr. Nicole Ehrhart’s preclinical study affirms AlloStem Cellular Bone Allograft effectiveness: 5 key takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
